ORIC at a glance
Oric Pharmaceuticals, Inc. (ORIC, SEC CIK 1796280) filed its latest 10-K annual report on February 23, 2026, a 10-Q quarterly report on November 16, 2026, an 8-K current report on November 16, 2026 and Form 4 insider filings as recently as October 21, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- As of September 30, 2026, 27 institutional investment managers tracked by SignalX reported holding Oric Pharmaceuticals, Inc. (ORIC) shares worth $555.2 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Piscitelli Dominic on October 20, 2026 of 14,000 shares at $13.53 per share.
- In the last 90 days, ORIC insiders reported 0 open-market purchases ($0) and 7 open-market sales ($1.5M) on Form 4, a net sale of $1.5M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Insiders · 90 days
- 0 buys · 7 sells
- Net −$1.5M
- 13F holders
- 27 funds
- $555.2M · +1 vs prior quarter
- Latest 8-K
- Nov 16, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Revenue $0, unchanged YoY, no product candidates commercialized
- Net loss $48.1M vs $32.6M YoY, operating expenses $51.6M vs $36.7M
- Rinzimetostat R&D $21.2M, up $15.6M YoY, largest program spending
- Operating cash use $106.0M, cash and investments sufficient into second half of 2028
- Himalayas-1 Phase 3 underway, Redwood-1 planned first half of 2027, funding needs and development costs rising
Risk Factors
- New regulatory risk: 2026 FDA workforce reductions and policy changes could delay reviews, inspections, and regulatory correspondence
- Most materially updated compliance risk: CMS proposed 2029 Medicare negotiation rules, increasing uncertainty over future drug pricing
- Operational risk: Competitors’ greater AI use in pharmaceutical development could disadvantage ORIC’s limited AI adoption
- Financial risk: $345.4 million in cash, equivalents, and investments expected to fund operations into the second half of 2028
- Legal risk: EU GDPR violations could trigger fines up to €20,000,000 or 4% of worldwide annual turnover
AI summary of the ORIC 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Press release announces Oric Pharmaceuticals’ financial results for quarter ended September 30, 2026
- Investors should review Exhibit 99.1 for earnings figures, cash position and operational updates
Item EX-99.1: Item EX-99.1
- Rinzimetostat Phase 3 Himalayas-1 initiated in approximately 600 post-abiraterone mCRPC patients, with Bayer supplying NUBEQA at no cost
- Preliminary rPFS remained competitive with mevrometostat: 10-month rates 59% post-abiraterone and 59% post-AR inhibitor
Item 8.01: Other Events
- Phase 1b efficacy: 84% investigator ORR and 80% BICR ORR across 25 response-evaluable patients
- Intracranial activity: 67% BICR RANO-BM ORR and 40% complete response rate across 15 patients
Item EX-99.1: Item EX-99.1
- Phase 1b data support rapid advancement toward Phase 3 in first-line EGFR atypical NSCLC
- Systemic confirmed ORR 84%, BICR ORR 80%, and 6-month PFS 88% in 25 evaluable patients
Item 7.01: Regulation FD Disclosure
- Enozertinib (ORIC-114) program update presented at ESMO Congress 2026 on October 23, 2026
- Exhibit 99.1 contains the disclosed clinical data, relevant to assessing enozertinib’s development progress
Item EX-99.1: Item EX-99.1
- Phase 3 Himalayas-1 initiated in approximately 600 mCRPC patients across 25 countries, materially advancing rinzimetostat toward registration
- Bayer supplying NUBEQA at no cost, preserving ORIC’s full global rights while reducing trial drug-supply expense
Item 2.02: Results of Operations and Financial Condition
- Press release announces ORIC Pharmaceuticals’ financial results for quarter ended June 30, 2026
- Exhibit 99.1 contains the detailed financial results and management commentary
AI summaries of ORIC 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for ORIC
Don't miss the next ORIC filing
- Alerts as it files. A push when ORIC files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut ORIC, by share count.
- Ask anything. An AI agent that reads every ORIC filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Piscitelli Dominic | Sell | Oct 20, 2026 | 14,000 | $13.53 |
| Piscitelli Dominic | M | Oct 20, 2026 | 14,000 | $4.36 |
| Piscitelli Dominic | M | Oct 20, 2026 | 14,000 | - |
| Heyman Richard A. | Sell | Oct 1, 2026 | 3,500 | $12.91 |
| Heyman Richard A. | Sell | Oct 1, 2026 | 3,200 | $12.91 |
| Heyman Richard A. | M | Oct 1, 2026 | 3,500 | $1.60 |
| Heyman Richard A. | M | Oct 1, 2026 | 3,500 | - |
| Piscitelli Dominic | M | Sep 28, 2026 | 13,400 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Operating Income | -$110.8M | -$142.9M | -$143.0M |
| Net Income | -$100.7M | -$127.8M | -$129.5M |
| Balance Sheet | |||
| Total Assets | $252.0M | $274.1M | $408.9M |
| Equity | $224.1M | $243.1M | $384.4M |
| ROE | -44.9% | -52.6% | -33.7% |
| Per Share | |||
| EPS | $-1.96 | $-1.83 | $-1.47 |
| Cash Flow | |||
| Operating CF | -$85.7M | -$112.7M | -$111.0M |
| CapEx | - | $1.2M | $712K |
Source: XBRL data in Oric Pharmaceuticals, Inc. (ORIC)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate ORIC share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 27 | $555.2M |
| Q2 2026 | 26 | $515.0M |
| Q1 2026 | 26 | $550.1M |
| Q4 2025 | 23 | $347.0M |
| Q3 2025 | 24 | $463.7M |
| Q2 2025 | 26 | $334.6M |
| Q1 2025 | 23 | $133.5M |
| Q4 2024 | 18 | $162.5M |
- D.E. Shaw & Co+873.7K (+55%)
- Morgan Stanley+242.2K (+14%)
- AQR Capital Management+229.9K (+64%)
- BlackRock+155.5K (+2%)
- Vanguard Capital Management LLC+121.5K (+3%)
- Viking Global Investors−1.56M (-31%)
- T. Rowe Price Group−1.53M (-23%)
- State Street Corp−767.7K (-16%)
- Goldman Sachs Group−650.2K (-27%)
- Citadel Advisors LLC−484.0K (-19%)
- Ameriprise Financial+455.7K
- U.S. Bancorp+119
- FMR LLC (Fidelity)−2.64M
Source: 13F-HR filings on SEC EDGAR (aggregated from 193 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
ORIC filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Nov 16, 2026 | - | Analysis | - |
| 10-Q | Nov 16, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Oct 23, 2026 | - | Analysis | - |
| 4 | Oct 21, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Sep 29, 2026 | - | - | - |
| 4 | Sep 25, 2026 | - | - | - |
| 4 | Aug 28, 2026 | - | - | - |
| 10-Q | Aug 3, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 3, 2026 | - | Analysis | - |
| 8-K | Jul 30, 2026 | - | Analysis | - |
| 4 | Jul 28, 2026 | - | - | - |
| 4 | Jul 8, 2026 | - | - | - |
| 8-K | Jun 22, 2026 | - | Analysis | - |
| SC 13G | May 15, 2026 | - | - | |
| 10-Q | May 4, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 4, 2026 | - | Analysis | - |
| 8-K | Mar 31, 2026 | - | - | - |
| 4 | Feb 26, 2026 | - | - | - |
| 8-K | Feb 23, 2026 | - | Analysis | - |
| 10-K | Feb 23, 2026 | Dec 31, 2025 | - | |
| 8-K | Feb 23, 2026 | - | Analysis | - |
| SC 13G | Jan 21, 2026 | - | - | |
| 4 | Jan 20, 2026 | - | - | |
| 4 | Jan 6, 2026 | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
ORIC SEC filings: frequently asked questions
Are ORIC insiders buying or selling?
In the last 90 days, Oric Pharmaceuticals, Inc. (ORIC) officers, directors and 10% owners reported no open-market purchases and 7 open-market sales worth $1.5 million by 2 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold ORIC stock?
As of September 30, 2026, the largest Oric Pharmaceuticals, Inc. (ORIC) holders among the 13F filers tracked by SignalX were BlackRock ($94.0 million), T. Rowe Price Group ($68.5 million), State Street Corp ($55.6 million), Vanguard Capital Management LLC ($54.9 million), Viking Global Investors ($48.0 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What did ORIC report in its latest 8-K?
Oric Pharmaceuticals, Inc. (ORIC) filed an 8-K on November 16, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Press release announces Oric Pharmaceuticals’ financial results for quarter ended September 30, 2026.
What are the latest ORIC SEC filings?
Oric Pharmaceuticals, Inc. (ORIC) filed its latest 10-K annual report on February 23, 2026, a 10-Q quarterly report on November 16, 2026, an 8-K current report on November 16, 2026 and a Form 4 insider filing on October 21, 2026.
What is ORIC's SEC CIK number?
Oric Pharmaceuticals, Inc. (ORIC)'s SEC Central Index Key (CIK) is 1796280. EDGAR lists every ORIC filing under that number.
Ask anything about ORIC
The research agent reads ORIC's filings, financials, insider trades and 13F holders, then answers with sources.